AAMU
CTIC

Amundi Asset Management US’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Amundi Asset Management US’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-51,000
Closed -$110K – 1733
2018
Q3 		$110K Buy
51,000
+28,600
+128% +$70.8K ﹤0.01% 1512
2018
Q2 		$112K Buy
+22,400
New +$98K ﹤0.01% 1461

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amundi Asset Management US's CTIC Position: Q4 2018 in Review

Amundi Asset Management US sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2018, closing a stake of 51,000 shares — an estimated $110K sold.

Amundi Asset Management US first reported a position in CTIC in Q2 2018 and held it in 2 quarters. The position peaked at $112K in Q2 2018. 75 funds tracked by Wall St. Rank hold CTIC as of Q4 2018.

  • Amundi Asset Management US reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 51,000 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2018, an estimated $110K.
  • Amundi Asset Management US first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2018 and held it in 2 quarters.
  • Amundi Asset Management US's CTI BioPharma Corp. (DE) Common Stock position peaked at $112K in Q2 2018.
  • 75 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.